




PHARMACEUTICAL 2020

Propanc Biopharma Inc.
Rank 352 of 358





PHARMACEUTICAL 2020

Propanc Biopharma Inc.
Rank 352 of 358

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 590% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 385% points.

The company's Economic Capital Ratio, given in the ranking table, is -568%, being 605% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	91
Cost of Goods Sold	28
Intangible Assets	0
Liabilities, Current	4,403
Liabilities, Non-Current	0
Other Assets	2.1
Other Compr. Net Income	709
Other Expenses	-115
Other Liabilities	0
Other Net Income	-3,259
Other Revenues	0
Property and Equipment	8.4
Research and Development	260
Selling, General and Administrative Expense	2,326

Output Variable	Value in 1000 USD
Assets	102
Liabilities	4,403
Expenses	2,499
Revenues	0
Stockholders Equity	-4,301
Net Income	-5,758
Comprehensive Net Income	-5,404
Economic Capital Ratio	-568%